Targeted treatments for multiple myeloma: specific role of carfilzomib

Targeted treatments for multiple myeloma: specific role of carfilzomib

Dhivya Sugumar,1 Jesse Keller,2 Ravi Vij2 1Department of Internal Medicine, St Mary’s Health Center, 2Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA Abstract: Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved...

Full description

Bibliographic Details
Main Authors:	Sugumar D, Keller J, Vij R
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-01-01
Series:	Pharmacogenomics and Personalized Medicine
Online Access:	http://www.dovepress.com/targeted-treatments-for-multiple-myeloma-specific-role-of-carfilzomib-peer-reviewed-article-PGPM

Similar Items

The role of carfilzomib in relapsed/refractory multiple myeloma
by: Andrew J. Yee
Published: (2021-06-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
by: Fostier K, et al.
Published: (2012-09-01)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
by: Gupta VA, et al.
Published: (2013-05-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
by: Steiner RE, et al.
Published: (2017-02-01)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
by: Jenny Z. Yang, et al.
Published: (2021-09-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka A, et al.
Published: (2013-01-01)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
by: Xiang Zhou, et al.
Published: (2020-04-01)

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
by: Bo Hu, et al.
Published: (2013-01-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
by: Giulia Mingrone, et al.
Published: (2021-04-01)

Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
by: Zhao F, et al.
Published: (2018-05-01)

Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
by: Eric H. Yang, et al.
Published: (2018-03-01)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
by: Vladimir Liberman, et al.
Published: (2016-07-01)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
by: Michael Rassner, et al.
Published: (2021-01-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: D.S. Siegel, et al.
Published: (2020-11-01)

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
by: M. Turgut, et al.
Published: (2020-10-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
by: A. Maiolino, et al.
Published: (2020-11-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
by: Qian Li, et al.
Published: (2018-05-01)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
by: Harvey RD
Published: (2014-05-01)

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
by: Imtiaz H, et al.
Published: (2021-10-01)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
by: H. Quach, et al.
Published: (2020-11-01)

A phase 1/2 study of ixazomib as a replacement for bortezomib or carfilzomib for multiple myeloma patients recently relapsed or refractory to their last combination regimen containing either bortezomib or carfilzomib
by: Forouzan, Eli
Published: (2020)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
by: Lu Gao, et al.
Published: (2015-01-01)

The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma
by: Teruhito Takakuwa, et al.
Published: (2019-01-01)

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
by: Anna Astarita, et al.
Published: (2021-04-01)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
by: Evangelos Terpos, et al.
Published: (2021-03-01)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
by: Giulia Bruno, et al.
Published: (2019-05-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network
by: Zheng Z, et al.
Published: (2017-03-01)

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting
by: Robert M. Rifkin, et al.
Published: (2019-01-01)

Carfilzomib en el tratamiento de mieloma múltiple: revisión sistemática de la literatura y experiencia colombiana basada en RIPS / Carfilzomib for the Treatment of Multiple Myeloma: Systematic Review of the Literature and Colombian Experience Based on RIPS / Carfilzomib no tratamento do mieloma múltiplo: revisão da literatura e da experiência colombiana baseada em RIPS
by: Camilo Castañeda, MD., et al.
Published: (2014-11-01)

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
by: Xuxing Shen, et al.
Published: (2021-04-01)